BRÈVE

sur Jolt Health Inc. (isin : CA3779041076)

Jolt Health Inc. Acquires Revolutionary HCQ Transdermal Patch Technology

Jolt Health Inc., a prominent biotechnology firm, announced an acquisition of intellectual property for developing transdermal delivery systems for hydroxychloroquine (HCQ) and chloroquine (CQ), targeting the management of malaria, lupus, and rheumatoid arthritis. With an arms-length agreement dated April 16, 2024, this acquisition aims to enhance Jolt’s health and wellness portfolio significantly.

The technology involves transdermal and oral mucosal delivery methods that could potentially tackle common side effects associated with the current oral tablet form of HCQ, such as nausea and dizziness. By bypassing the gastrointestinal system, this new method promises a safer, more consistent dosage that could vastly improve patient outcomes.

Jolt Health plans to pursue FDA approval for this technology through the 505(b)(2) accelerated pathway. The market implications are substantial, with the HCQ market projected to attain $6 billion by 2027. This initiative marks a strategic expansion in Jolt Health’s biotechnology assets, focusing on better service delivery and patient care in underaddressed ailments.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Jolt Health Inc.